| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS30003686 | HIV | ENSG00000138735.16 | protein_coding | PDE5A | No | No | 8654 | G5E9C5 O76074 |
| TVIS30088900 | HIV | ENSG00000138735.16 | protein_coding | PDE5A | No | No | 8654 | G5E9C5 O76074 |
| TVIS30076730 | HIV | ENSG00000138735.16 | protein_coding | PDE5A | No | No | 8654 | G5E9C5 O76074 |
| TVIS30060933 | HIV | ENSG00000138735.16 | protein_coding | PDE5A | No | No | 8654 | G5E9C5 O76074 |
| TVIS30060934 | HIV | ENSG00000138735.16 | protein_coding | PDE5A | No | No | 8654 | G5E9C5 O76074 |
| TVIS20011880 | HPV | ENSG00000138735.16 | protein_coding | PDE5A | No | No | 8654 | G5E9C5 O76074 |
| TVIS20058749 | HPV | ENSG00000138735.16 | protein_coding | PDE5A | No | No | 8654 | G5E9C5 O76074 |
| TVIS44036219 | HTLV-1 | ENSG00000138735.16 | protein_coding | PDE5A | No | No | 8654 | G5E9C5 O76074 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | PDE5A |
|---|---|
| DrugBank ID | DB06267 |
| Drug Name | Udenafil |
| Target ID | BE0000182 |
| UniProt ID | O76074 |
| Regulation Type | inhibitor |
| PubMed IDs | 18491987; 11752352; 19465935; 21054754; 19860692 |
| Citations | Gur S, Sikka SC, Hellstrom WJ: Novel phosphodiesterase-5 (PDE5) inhibitors in the alleviation of erectile dysfunction due to diabetes and ageing-induced oxidative stress. Expert Opin Investig Drugs. 2008 Jun;17(6):855-64. doi: 10.1517/13543784.17.6.855 .@@Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.@@Ahn GJ, Chung HK, Lee CH, Kang KK, Ahn BO: Increased expression of the nitric oxide synthase gene and protein in corpus cavernosum by repeated dosing of udenafil in a rat model of chemical diabetogenesis. Asian J Androl. 2009 Jul;11(4):435-42. doi: 10.1038/aja.2009.27. Epub 2009 May 25.@@Zhao C, Kim SH, Lee SW, Jeon JH, Kang KK, Choi SB, Park JK: Activity of phosphodiesterase type 5 inhibitors in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. BJU Int. 2011 Jun;107(12):1943-7. doi: 10.1111/j.1464-410X.2010.09759.x. Epub 2010 Nov 5.@@Kouvelas D, Goulas A, Papazisis G, Sardeli C, Pourzitaki C: PDE5 inhibitors: in vitro and in vivo pharmacological profile. Curr Pharm Des. 2009;15(30):3464-75. |
| Groups | Approved; Investigational |
| Direct Classification | Benzenesulfonamides |
| SMILES | CCCOC1=C(C=C(C=C1)S(=O)(=O)NCCC1CCCN1C)C1=NC(=O)C2=C(N1)C(CCC)=NN2C |
| Pathways | |
| PharmGKB | PA164776753 |
| ChEMBL | CHEMBL2103849 |
